CA Patent

CA3156436A1 — Methods of treatment using an mtorc1 modulator

Assigned to Navitor Pharmaceuticals Inc · Expires 2021-05-06 · 5y expired

What this patent protects

The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.

USPTO Abstract

The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CA3156436A1
Jurisdiction: CA
Classification: —
Expires: 2021-05-06
Drug substance claim: No
Drug product claim: No
Assignee: Navitor Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.